Oxygen Double Bonded Directly To The Ring (i.e., The Carbon Of The Additional Carbonyl Is Part Of The Ring; E.g., Homo Prostaglandins, Etc.) Patents (Class 554/118)
  • Patent number: 8592483
    Abstract: The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: November 26, 2013
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Patent number: 8202909
    Abstract: The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound.
    Type: Grant
    Filed: January 26, 2006
    Date of Patent: June 19, 2012
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Patent number: 7820839
    Abstract: The invention relates to a second-generation-fatty acid conjugate and pharmaceutical compositions thereof. The second-generation-fatty acid conjugate are useful in the treatment of cancer in a human in need thereof.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: October 26, 2010
    Assignee: The Research Foundation of State University of New York
    Inventor: Iwao Ojima
  • Publication number: 20100168045
    Abstract: The invention concerns novel polyunsaturated compounds of formula (I) wherein: R1 represents a R?1, -A-R?1 group, R?1 being selected from —COOH, —COOR3, —CONH2, —CONHR3, —CONR3, R4, —CHO, —CH2OH, —CH2OR5, and A represents a C2-C16 alkylene, alkenylene or alkynylene; R2 represents: an optionally substituted aryl group or an optionally substituted heteroaryl group; a sugar residue or, a fatty acid residue optionally branched and/or substituted preferably at the chain terminus and particularly by hydroxy, acetoxy radical or by an optionally protected amino radical; a —OC—(CH2)n CO-tocopheryl (alpha, beta or gamma or delta) group, with 2 $m(F) n $m(F) 10; a —R?2—O—R6 group, wherein R?2 is an optionally substituted arylene group or an optionally substituted heteroarylene group, and R6 represents a hydrogen atom, a straight or branched optionally substituted C1-C16 alkyl, a straight or branched optionally substituted C2-C16 alkenyl, or a straight or branched C2-C16 alkynyl group, an optionally substituted tocophery
    Type: Application
    Filed: December 14, 2006
    Publication date: July 1, 2010
    Applicant: Pierre Fabre Dermo-Cosmetique
    Inventors: Pascal Bordat, Roger Tarroux, Jean-Hilaire Saurat, Olivier Sorg, Jean-Louis Brayer, Natacha Frison
  • Patent number: 7635716
    Abstract: Novel compounds, and therapeutic methods, compositions and medicament related thereto are disclosed herein.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: December 22, 2009
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Todd S. Gac, Vinh X. Ngo
  • Patent number: 7605178
    Abstract: Disclosed herein are compounds of the formula therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: October 20, 2009
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Vinh X. Ngo
  • Patent number: 7569711
    Abstract: Described herein are new enone derivatives and conjugates. Additionally, methods for synthesizing these new enones are also disclosed. These compounds can be employed in cancer therapy.
    Type: Grant
    Filed: December 7, 2004
    Date of Patent: August 4, 2009
    Assignee: Cornell Univeristy
    Inventors: Bruce Ganem, Donald J. Creighton, Diana S. Hamilton, Zhebo Ding
  • Patent number: 7498360
    Abstract: A novel method and compositions for the local treatment of Meniere's disease, tinnitus and hearing loss are described. The treatment is based on the administration of a therapeutically effective amount of a prostaglandin of the F-type to the inner ear. The treatment can be either continuous or intermittent and may involve the use of pumps, gels, or slow release drug inserts.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: March 3, 2009
    Assignee: Synphora AB
    Inventors: Helge Rask-Andersen, Johan Stjernschantz
  • Patent number: 7396946
    Abstract: Disclosed is a method for treatment of external secretion disorders, which comprises administering a fatty 5 acid derivative to a subject in need of said treatment. The method of the present invention is useful for treatment of at least one condition selected from hypolacrimation including disorder of basal tear secretion, dry-eye syndrome, hyposalivation and dry-mouth syndrome.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: July 8, 2008
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Patent number: 6083501
    Abstract: A drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation, as well as a model animal of fibrinoid formation or thrombus formation in the lung is disclosed. The drug for preventing and treating diseases caused by fibrinoid formation or thrombus formation in the lung according to the present invention comprises an inhibitor of interleukin 6 as an effective ingredient. The model animal of the diseases caused by fibrinoid formation or thrombus formation in the lung is a rat in which fibrinoid formation or thrombus formation actually occurs by induction with interleukin 6.
    Type: Grant
    Filed: March 14, 1996
    Date of Patent: July 4, 2000
    Assignee: Toray Industries, Inc.
    Inventors: Masayuki Miyata, Reiji Kasukawa, Masanobu Naruto, Nobutaka Ida, Yu-ichiro Sato, Katsuaki Kojima, Nobuo Ida
  • Patent number: 5990329
    Abstract: Compounds of the formula: ##STR1## wherein R.sup.2 and X are as described, are disclosed. The compounds are useful for treating dermatological disorders which are accompanied by epithelial lesions, e.g., acne and psoriasis, as well as malignant and premalignant epithelial lesions, tumours and precancerous changes of the mucous membrane in the mouth, tongue, larynx, oesophagus, bladder, cervix and colon.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: November 23, 1999
    Assignee: Hoffman-La Roche Inc.
    Inventors: Michael Klaus, Peter Mohr
  • Patent number: 5292915
    Abstract: The invention relates to compounds containing carbonate groups and carbonyl groups and having the general formula ##STR1## in which R stands for a C.sub.1 -C.sub.4 -alkyl radical, an aryl radical, or a radical R.sup.1, whereR.sup.1 has the following formula ##STR2## in which R.sup.2 to R.sup.6 stand for H, alkyl, OH, O-alkyl, SH, S-alkyl, halogen, N(alkyl).sub.2, or N(alkyl)(aryl) and at least one but not more than three of the radicals R.sup.2 to R.sup.6 stand for a radical of the formula ##STR3## in which A, B and C stand for alkylene, cycloalkylene, oxaalkylene, polyoxaalkylene or arylene, k and l both stand for an integer from 1 to 80, and the end group Z stands for alkyl, aryl, alkoxycarbonyl, alkoxycarbonyloxy, or aryl.These compounds are suitable for use as emulsifiers for dispersions.
    Type: Grant
    Filed: February 4, 1992
    Date of Patent: March 8, 1994
    Assignee: BASF Aktiengesellschaft
    Inventors: Andreas Boettcher, Manfred Schwartz
  • Patent number: 5212324
    Abstract: A compound for treatment of a cataract which is a 15-ketoprostaglandin compound.
    Type: Grant
    Filed: April 3, 1991
    Date of Patent: May 18, 1993
    Assignee: R.-Tech Ueno Ltd.
    Inventor: Ryuji Ueno
  • Patent number: 5124083
    Abstract: There are disclosed 3-substituted and 3,3-disubstituted all-trans-4-oxoretinoic acids and 3-substituted and 3,3-disubstituted 13-cis-4-oxoretinoic acids and their lower alkyl esters.
    Type: Grant
    Filed: August 30, 1990
    Date of Patent: June 23, 1992
    Assignee: Southern Research Institute
    Inventor: Y. Fulmer Shealy